Related Experiment Video
Updated: Jan 11, 2026

Generation of a Rat Model of Acute Liver Failure by Combining 70% Partial Hepatectomy and Acetaminophen
Published on: November 27, 2019
Protein Induced by Vitamin K Absence or Antagonist-II: Significantly Elevated in Obstructive Jaundice and Sepsis
Ke Zhang1, Xiarui Ye1, Xianran Fu1
1Department of Clinical Laboratory, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
Background:
PIVKA-II is a promising diagnostic and prognostic biomarker for HCC. However, a particular PIVKA-II variant can be abnormally elevated in patients with obstructive jaundice or sepsis, complicating its interpretation in HCC conditions.
Methods:
This study aimed to investigate the distribution and positive rates of serum PIVKA-II and AFP in patients with obstructive jaundice or sepsis, and to explore their relationships with laboratory tests, particularly coagulation function indexes. The receiver operating characteristic (ROC) curve was used to determine the cut-off, specificity and sensitivity of PIVKA-II in diagnosing HCC.
Results:
In patients with obstructive jaundice and sepsis, PIVKA-II was significantly positively correlated with PT and INR. When the cut-off was 42.17 mAU/mL, the sensitivity and specificity of PIVKA-II in diagnosing HCC were 74.69% and 70.17%, respectively. There was no difference in PIVKA-II concentration between HCC and obstructive jaundice. PIVKA-II levels in obstructive jaundice and sepsis were significantly higher than those in healthy controls. Except for healthy individuals, the positive rate of serum PIVKA-II was significantly higher than that of AFP among the other three groups, and patients with obstructive jaundice had the highest positive rate of PIVKA-II.
Conclusions:
The PIVKA-II produced by HCC may differ from that produced by obstructive jaundice and sepsis. Given that PIVKA-II levels are abnormally elevated in patients with obstructive jaundice and sepsis, the results should be interpreted with caution in patients with HCC combined with these diseases.
Related Concept Videos
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Vitamins
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug

